Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | GALK1 | P51570 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3136339 | 0.82 | MAPT (0.46) | MAPTSMN1; SMN2ALDH1A1TP53LMNA | |
| SCHEMBL743918 | 0.80 | CA2 (0.67) | CA2AKR1B1CCR2 | |
| SCHEMBL329398 | 0.67 | MAPT (0.47) | MAPTSMN1; SMN2ALDH1A1TP53LMNA | |
| SCHEMBL25119616 | 0.67 | CA2 (0.67) | CA2AKR1B1CCR2PSMB8 | |
| SCHEMBL329294 | 0.67 | CA2 (0.71) | CA2AKR1B1CCR2 | |
| SCHEMBL29742225 | 0.66 | IKBKB (0.51) | MAPTSMN1; SMN2ALDH1A1TP53LMNA | |
| SCHEMBL19961702 | 0.66 | IKBKB (0.51) | MAPTSMN1; SMN2ALDH1A1TP53LMNA | |
| SCHEMBL305334 | 0.66 | LMNA (0.53) | MAPTSMN1; SMN2ALDH1A1TP53LMNA | |
| SCHEMBL329399 | 0.66 | MAPT (0.46) | MAPTSMN1; SMN2ALDH1A1TP53LMNA | |
| SCHEMBL31665885 | 0.66 | MAPT (0.46) | MAPTSMN1; SMN2ALDH1A1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2174936-A1 | PNA monomer and precursor | Panagene, Inc. (KR) | 2010-04-14 | — | — | EP | disclosed |
| EP-1501812-B1 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2009-12-30 | — | — | EP | disclosed |
| US-7411065-B2 | Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids | PANAGENE, INC. (KR) | 2008-08-12 | — | — | US | disclosed |
| US-7371860-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7371859-B2 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7179896-B2 | Method of making PNA oligomers | PANAGENE, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-7145006-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-12-05 | — | — | US | disclosed |
| US-7125994-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-10-24 | — | — | US | disclosed |
| EP-1501812-A4 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2006-05-24 | — | — | EP | disclosed |
| US-20060030709-A1 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | PANAGENE, INC. (KR) | 2006-02-09 | — | — | US | disclosed |
| US-20060008835-A1 | PNA monomer and precursor | KIM SUNG K | 2006-01-12 | — | — | US | disclosed |
| US-20060003374-A1 | Method of making PNA oligomers | KIM SUNG K | 2006-01-05 | — | — | US | disclosed |
| US-20050283005-A1 | PNA monomer and precursor | KIM SUNG K | 2005-12-22 | — | — | US | disclosed |
| US-6969766-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-29 | — | — | US | disclosed |
| US-20050250785-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-10 | — | — | US | disclosed |
| US-20050250786-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-10 | — | — | US | disclosed |
| EP-1501812-A1 | PNA MONOMER AND PRECURSOR | Panagene, Inc. (KR) | 2005-02-02 | — | — | EP | disclosed |
| US-20030225252-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2003-12-04 | — | — | US | disclosed |
| WO-2003091231-A1 | PNA MONOMER AND PRECURSOR | PANAGENE, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030709-A1 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | RNGTT, POLL, RNMT | CA2 3213/4885AKR1B1 2272/4885MAPT 4141/4885 |
| US-20050283005-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | CA2 3950/4885AKR1B1 735/4885MAPT 4291/4885 |
| US-20050250785-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | CA2 3950/4885AKR1B1 735/4885MAPT 4291/4885 |
| US-20030225252-A1 | PNA monomer and precursor | PNISR, RNGTT, NCL | CA2 3930/4885AKR1B1 1148/4885MAPT 4396/4885 |
| US-20060008835-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | CA2 3950/4885AKR1B1 735/4885MAPT 4291/4885 |
| US-20050250786-A1 | PNA monomer and precursor | PNISR, RNGTT, NPR1 | CA2 3782/4885AKR1B1 426/4885MAPT 4051/4885 |
| US-20060003374-A1 | Method of making PNA oligomers | RNGTT, POLL, PNISR | CA2 3612/4885AKR1B1 627/4885MAPT 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.